We report the first measurement of the azimuthal anisotropy of J/psi at forward rapidity (1.2 < vertical bar eta vertical bar < 2.2) in Au + Au collisions at root s(NN) = 200 GeV at the BNL Relativistic Heavy Ion Collider. The data were collected by the PHENIX experiment in 2014 and 2016 with integrated luminosity of 14.5 nb(-1). The second Fourier coefficient (v(2)) of the azimuthal distribution of J/psi is determined as a function of the transverse momentum (p(T)) using the event-plane method. The measurements were performed for several selections of collision centrality: 0%-50%, 10%-60%, and 10%-40%. We find that in all cases the values of v(2) (p(T)), which quantify the elliptic flow of J/psi, are consistent with zero. Within uncertainties, the results are consistent with measurements at midrapidity, indicating no significant elliptic flow of the J/psi within the quark-gluon-plasma medium at collision energies of root s(NN) = 200 GeV.

The jet cross section and jet-substructure observables in p +p collisions at root s =200 GeV were measured by the PHENIX Collaboration at the Relativistic Heavy Ion Collider (RHIC). Jets are reconstructed from charged-particle tracks and electromagnetic-calorimeter clusters using the anti-k(t) algorithm with a jet radius of R =0.3 for jets with transverse momentum within 8.0 < p(T) <40.0 GeV/c and pseudorapidity |eta| <0.15. Measurements include the jet cross section, as well as distributions of SoftDrop-groomed momentum fraction (z(g)), charged-particle transverse momentum with respect to jet axis (j(T)), and radial distributions of charged particles within jets (r). Also measured was the distribution of xi =-ln(z), where z is the fraction of the jet momentum carried by the charged particle. The measurements are compared to theoretical next-to and next-to-next-to-leading-order calculations, the pythia and herwig event generators, and to other existing experimental results. Indicated from these measurements is a lower particle multiplicity in jets at RHIC energies when compared to models. Also noted are implications for future jet measurements with sPHENIX at RHIC as well as at the future Electron-Ion Collider.

We present the first forward-rapidity measurements of elliptic anisotropy of open-heavy-flavor muons at the Relativistic Heavy Ion Collider. The measurements are based on data samples of Au + Au collisions at root s(NN) = 200 GeV collected by the PHENIX experiment in 2014 and 2016 with integrated luminosity of 14.5 nb(-1). The measurements are performed in the pseudorapidity range 1.2 < vertical bar eta vertical bar < 2 and cover transverse momenta 1 < p(T) < 4 GeV/c. The elliptic flow of charged hadrons as a function of transverse momentum is also measured in the same kinematic range. We observe significant elliptic flow for both charged hadrons and heavy-flavor muons. The results show clear mass ordering of elliptic flow of light- and heavy-flavor particles. The magnitude of the measured v(2) is comparable to that in the midrapidity region. This indicates that there is no strong longitudinal dependence in the quark-gluon-plasma evolution between midrapidity and the rapidity range of this measurement at root s(NN) = 200 GeV.

High-momentum two-particle correlations are a useful tool for studying jet-quenching effects in the quark-gluon plasma. Angular correlations between neutral-pion triggers and charged hadrons with transverse momenta in the range 4–12 GeV/c and 0.5–7 GeV/c, respectively, have been measured by the PHENIX experiment in 2014 for Au+Au collisions at √(s__NN)=200 GeV. Suppression is observed in the yield of high-momentum jet fragments opposite the trigger particle, which indicates jet suppression stemming from in-medium partonic energy loss, while enhancement is observed for low-momentum particles. The ratio and differences between the yield in Au+Au collisions and p+p collisions, I_AA and Δ_AA, as a function of the trigger-hadron azimuthal separation, Δϕ, are measured for the first time at the Relativistic Heavy Ion Collider. These results better quantify how the yield of low-p_T associated hadrons is enhanced at wide angle, which is crucial for studying energy loss as well as medium-response effects.

The PHENIX experiment measured the centrality dependence of two-pion Bose-Einstein correlation functions in root sNN = 200 GeV Au + Au collisions at the Relativistic Heavy Ion Collider at Brookhaven National Laboratory. The data are well represented by Levy-stable source distributions. The extracted source parameters are the correlation-strength parameter lambda, the Levy index of stability a, and the Levy-scale parameter R as a function of transverse mass m(T) and centrality. The lambda(m(T)) parameter is constant at larger values of m(T), but decreases as m(T) decreases. The Levy-scale parameter R(m(T)) decreases with mT and exhibits proportionality to the length scale of the nuclear overlap region. The Levy exponent alpha(m(T)) is independent of m(T) within uncertainties in each investigated centrality bin, but shows a clear centrality dependence. At all centralities, the Levy exponent a is significantly different from that of Gaussian ( alpha= 2) or Cauchy ( alpha = 1) source distributions. Comparisons to the predictions of Monte-Carlo simulations of resonance-decay chains show that, in all but the most peripheral centrality class (50%-60%), the obtained results are inconsistent with the measurements, unless a significant reduction of the in-medium mass of the eta meson is included. In each centrality class, the best value of the in-medium eta mass is compared to the mass of the. meson, as well as to several theoretical predictions that consider restoration of U-A(1) symmetry in hot hadronic matter.

High-momentum two-particle correlations are a useful tool for studying jet-quenching effects in the quarkgluon plasma. Angular correlations between neutral-pion triggers and charged hadrons with transverse momenta in the range 4-12 GeV/c and 0.5-7 GeV/c, respectively, have been measured by the PHENIX experiment in 2014 for Au + Au collisions at root sNN = 200 GeV. Suppression is observed in the yield of high-momentum jet fragments opposite the trigger particle, which indicates jet suppression stemming from in-medium partonic energy loss, while enhancement is observed for low-momentum particles. The ratio and differences between the yield in Au + Au collisions and p + p collisions, I-AA and Delta(AA), as a function of the trigger-hadron azimuthal separation, Delta phi, are measured for the first time at the BNL Relativistic Heavy Ion Collider. These results better quantify how the yield of low-pT associated hadrons is enhanced at wide angle, which is crucial for studying energy loss as well as medium-response effects.

The invariant yield of electrons from open-heavy-flavor decays for $1

The PHENIX experiment has performed a systematic study of identified charged-hadron ( p +/-, K +/-, p, p) production at midrapidity in p + Al, He-3+Au, and Cu + Au collisions at root s(NN) = 200 GeV and U + U collisions at root s(NN) = 193 GeV. Identified charged-hadron invariant transverse-momentum (p(T)) and transverse-mass (m(T)) spectra are presented and interpreted in terms of radially expanding thermalized systems. The particle ratios of K/ p and p/ p have been measured in different centrality ranges of large (Cu + Au and U + U) and small ( p + Al and He-3+Au) collision systems. The values of K/pi ratios measured in all considered collision systems were found to be consistent with those measured in p + p collisions. However, the values of p/pi ratios measured in large collision systems reach the values of approximate to 0.6, which is a factor of approximate to 2 larger than in p + p collisions. These results can be qualitatively understood in terms of the baryon enhancement expected from hadronization by recombination. Identified charged-hadron nuclear-modification factors (R-AB) are also presented. Enhancement of proton R-AB values over meson RAB values was observed in central He-3+Au, Cu + Au, and U + U collisions. The proton R-AB values measured in the p + Al collision system were found to be consistent with R-AB phi values of phi, pi(+/-), K-+/-, and pi(0) mesons, which may indicate that the size of the system produced in p + Al collisions is too small for recombination to cause a noticeable increase in proton production.

The measurement of the direct-photon spectrum from Au+Au collisions at root s(NN) = 200 GeV is presented by the PHENIX Collaboration using the external-photon-conversion technique for 0%-93% central collisions in a transverse-momentum (p(T)) range of 0.8-10 GeV/c. An excess of direct photons, above prompt-photon production from hard-scattering processes, is observed for p(T) < 6 GeV/c. Nonprompt direct photons are measured by subtracting the prompt component, which is estimated as Ncoll-scaled direct photons from p + p collisions at 200 GeV, from the direct-photon spectrum. Results are obtained for 0.8 < p(T) < 6.0 GeV/c and suggest that the spectrum has an increasing inverse slope from approximate to 0.2 to 0.4 GeV/c with increasing p(T), which indicates a possible sensitivity of the measurement to photons from earlier stages of the evolution of the collision. In addition, like the direct-photon production, the p(T) -integrated nonprompt direct-photon yields also follow a power-law scaling behavior as a function of collision-system size. The exponent, a, for the nonprompt component is found to be consistent with 1.1 with no apparent p(T) dependence.

1. Non-coding RNAs, such as miRNAs, play a crucial role in chicken feather growth rate. However, circular RNA (circRNA) expression profiles in fast- and slow-feathering chickens that follow and do not follow Mendelian inheritance are unclear.2. The circRNA expression profiles was analysed by RNA sequencing of hair follicles of slow-feathering chickens that follow genetic rules and fast-feathering chickens that did not follow genetic rules. Differentially expressed circRNA-miRNA-mRNA competing endogenous RNA (ceRNA) network was then constructed and the key factors and regulation mechanisms controlling feather growth rate were identified.3. The results revealed that 67 circRNAs were significantly differentially expressed in hens, including 22 up-regulated and 45 down-regulated circRNAs in non-Mendelian inheritance-mediated fast-feathering hens compared with Mendelian inheritance-mediated slow-feathering hens. In addition, 16 significantly differentially expressed circRNAs were identified in cockerels, including nine up-regulated and seven down-regulated circRNAs in non-Mendelian inheritance-mediated fast- compared with Mendelian inheritance-mediated slow-feathering cocks. Moreover, circRNA-mediated ceRNA regulation of hair follicle formation was particularly abundant in the Jak-STAT, Wnt and Toll-like receptor signalling pathways. Furthermore, circABI3BP was seen to be a crucial circRNA in regulating feather growth rate, by binding with gga-miR-1649-5p to regulate SSTR2 expression.4. In conclusion, this study analysed circRNA expression profiles in fast- and slow-feathering chickens that follow and do not follow Mendelian inheritance, which laid the foundation for understanding the role of circRNA in chicken feather growth rate.

Radiotherapy plays important role in comprehensive treatment for lung cancer. Abscopal effect reflects the systemic anti-tumor effect of radiotherapy and greatly extends the use of radiotherapy. However, the occurrence of abscopal effect is deemed too rare. Therefore, it is crucial to investigate abscopal effect in clinical settings. Finding those disincentives might be the key to abscopal effect.

TCF21 is a determinant of the malignant phenotype of CAFs in ESCC. Up-regulation of TCF21 expression is a promising approach of inhibiting the growth, migration and invasion, activation and radioresistance of CAFs in ESCC.

A. Adare,12 C. Aidala,39,45 N. N. Ajitanand,63,* Y. Akiba,57,58,† R. Akimoto,11 J. Alexander,63 M. Alfred,24 H. Al-Ta’ani,52 A. Angerami,13 K. Aoki,32,57 N. Apadula,29,64 Y. Aramaki,11,57 H. Asano,35,57 E. C. Aschenauer,7 E. T. Atomssa,64 T. C. Awes,54 B. Azmoun,7 V. Babintsev,25 A. Bagoly,17 M. Bai,6 B. Bannier,64 K. N. Barish,8 B. Bassalleck,51 S. Bathe,5,58 V. Baublis,56 S. Baumgart,57 A. Bazilevsky,7 R. Belmont,12,69 A. Berdnikov,60 Y. Berdnikov,60 D. S. Blau,34,50 M. Boer,39 J. S. Bok,51,52,72 K. Boyle,58 M. L. Brooks,39 J. Bryslawskyj,5,8 H. Buesching,7 V. Bumazhnov,25 S. Butsyk,51 S. Campbell,13,64 V. Canoa Roman,64 P. Castera,64 C.-H. Chen,58,64 C. Y. Chi,13 M. Chiu,7 I. J. Choi,26 J. B. Choi,10,* S. Choi,62 R. K. Choudhury,4 P. Christiansen,41 T. Chujo,68 O. Chvala,8 V. Cianciolo,54 Z. Citron,64,70 B. A. Cole,13 M. Connors,21,58,64 M. Csanád,17 T. Csörgő,18,71 S. Dairaku,35,57 T. W. Danley,53 A. Datta,44 M. S. Daugherity,1 G. David,7,64 K. DeBlasio,51 K. Dehmelt,64 A. Denisov,25 A. Deshpande,58,64 E. J. Desmond,7 K. V. Dharmawardane,52 O. Dietzsch,61 L. Ding,29 A. Dion,29,64 J. H. Do,72 M. Donadelli,61 L. D’Orazio,43 O. Drapier,36 A. Drees,64 K. A. Drees,6 J. M. Durham,39,64 A. Durum,25 S. Edwards,6 Y. V. Efremenko,54 T. Engelmore,13 A. Enokizono,54,57,59 S. Esumi,68 K. O. Eyser,7,8 B. Fadem,46 W. Fan,64 N. Feege,64 D. E. Fields,51 M. Finger,9 M. Finger, Jr.,9 F. Fleuret,36 S. L. Fokin,34 J. E. Frantz,53 A. Franz,7 A. D. Frawley,20 Y. Fukao,57 Y. Fukuda,68 T. Fusayasu,48 K. Gainey,1 C. Gal,64 P. Gallus,14 P. Garg,3,64 A. Garishvili,66 I. Garishvili,38 H. Ge,64 A. Glenn,38 X. Gong,63 M. Gonin,36 Y. Goto,57,58 R. Granier de Cassagnac,36 N. Grau,2 S. V. Greene,69 M. Grosse Perdekamp,26 T. Gunji,11 L. Guo,39 H.-Å. Gustafsson,41,* T. Hachiya,57,58 J. S. Haggerty,7 K. I. Hahn,19 H. Hamagaki,11 S. Y. Han,19 J. Hanks,13,64 S. Hasegawa,30 T. O. S. Haseler,21 K. Hashimoto,57,59 E. Haslum,41 R. Hayano,11 X. He,21 T. K. Hemmick,64 T. Hester,8 J. C. Hill,29 K. Hill,12 A. Hodges,21 R. S. Hollis,8 K. Homma,23 B. Hong,33 T. Horaguchi,68 Y. Hori,11 T. Hoshino,23 N. Hotvedt,29 J. Huang,7 S. Huang,69 T. Ichihara,57,58 H. Iinuma,32 Y. Ikeda,57,68 J. Imrek,16 M. Inaba,68 A. Iordanova,8 D. Isenhower,1 M. Issah,69 D. Ivanishchev,56 B. V. Jacak,64 M. Javani,21 Z. Ji,64 J. Jia,7,63 X. Jiang,39 B. M. Johnson,7,21 K. S. Joo,47 V. Jorjadze,64 D. Jouan,55 D. S. Jumper,26 J. Kamin,64 S. Kaneti,64 B. H. Kang,22 J. H. Kang,72 J. S. Kang,22 J. Kapustinsky,39 K. Karatsu,35,57 S. Karthas,64 M. Kasai,57,59 G. Kasza,17,18 D. Kawall,44,58 A. V. Kazantsev,34 T. Kempel,29 V. Khachatryan,64 A. Khanzadeev,56 K. M. Kijima,23 B. I. Kim,33 C. Kim,8,33 D. J. Kim,31 E.-J. Kim,10 H. J. Kim,72 K.-B. Kim,10 M. Kim,62 M. H. Kim,33 Y.-J. Kim,26 Y. K. Kim,22 D. Kincses,17 E. Kinney,12 Á. Kiss,17 E. Kistenev,7 J. Klatsky,20 D. Kleinjan,8 P. Kline,64 T. Koblesky,12 Y. Komatsu,11,32 B. Komkov,56 J. Koster,26 D. Kotchetkov,53 D. Kotov,56,60 A. Král,14 F. Krizek,31 S. Kudo,68 G. J. Kunde,39 B. Kurgyis,17 K. Kurita,57,59 M. Kurosawa,57,58 Y. Kwon,72 G. S. Kyle,52 R. Lacey,63 Y. S. Lai,13 J. G. Lajoie,29 A. Lebedev,29 B. Lee,22 D. M. Lee,39 J. Lee,19,65 K. B. Lee,33 K. S. Lee,33 S. H. Lee,29,64 S. R. Lee,10 M. J. Leitch,39 M. A. L. Leite,61 M. Leitgab,26 Y. H. Leung,64 B. Lewis,64 N. A. Lewis,45 X. Li,39 S. H. Lim,39,72 L. A. Linden Levy,12 M. X. Liu,39 S. Lökös,17,18 B. Love,69 D. Lynch,7 C. F. Maguire,69 Y. I. Makdisi,6 M. Makek,70,73 A. Manion,64 V. I. Manko,34 E. Mannel,7,13 H. Masuda,59 S. Masumoto,11,32 M. McCumber,12,39 P. L. McGaughey,39 D. McGlinchey,12,20,39 C. McKinney,26 M. Mendoza,8 B. Meredith,26 W. J. Metzger,18 Y. Miake,68 T. Mibe,32 A. C. Mignerey,43 D. E. Mihalik,64 A. Milov,70 D. K. Mishra,4 J. T. Mitchell,7 G. Mitsuka,58 Y. Miyachi,57,67 S. Miyasaka,57,67 A. K. Mohanty,4 S. Mohapatra,63 H. J. Moon,47 T. Moon,72 D. P. Morrison,7 S. I. Morrow,69 S. Motschwiller,46 T. V. Moukhanova,34 T. Murakami,35,57 J. Murata,57,59 A. Mwai,63 T. Nagae,35 K. Nagai,67 S. Nagamiya,32,57 K. Nagashima,23 J. L. Nagle,12 M. I. Nagy,17,71 I. Nakagawa,57,58 H. Nakagomi,57,68 Y. Nakamiya,23 K. R. Nakamura,35,57 T. Nakamura,57 K. Nakano,57,67 C. Nattrass,66 A. Nederlof,46 M. Nihashi,23,57 R. Nouicer,7,58 T. Novák,18,71 N. Novitzky,31,64 A. S. Nyanin,34 E. O’Brien,7 C. A. Ogilvie,29 K. Okada,58 J. D. Orjuela Koop,12 J. D. Osborn,45 A. Oskarsson,41 M. Ouchida,23,57 K. Ozawa,11,32,68 R. Pak,7 V. Pantuev,27 V. Papavassiliou,52 B. H. Park,22 I. H. Park,19,65 J. S. Park,62 S. Park,57,62,64 S. K. Park,33 S. F. Pate,52 L. Patel,21 M. Patel,29 H. Pei,29 J.-C. Peng,26 W. Peng,69 H. Pereira,15 D. V. Perepelitsa,7,12,13 G. D. N. Perera,52 D.Yu. Peressounko,34 C. E. PerezLara,64 R. Petti,7,64 C. Pinkenburg,7 R. P. Pisani,7 M. Proissl,64 A. Pun,53 M. L. Purschke,7 H. Qu,1 P. V. Radzevich,60 J. Rak,31 I. Ravinovich,70 K. F. Read,54,66 D. Reynolds,63 V. Riabov,50,56 Y. Riabov,56,60 E. Richardson,43 D. Richford,5 T. Rinn,29 D. Roach,69 G. Roche,40,* S. D. Rolnick,8 M. Rosati,29 Z. Rowan,5 J. Runchey,29 B. Sahlmueller,64 N. Saito,32 T. Sakaguchi,7 H. Sako,30 V. Samsonov,50,56 M. Sano,68 M. Sarsour,21 K. Sato,68 S. Sato,30 S. Sawada,32 B. K. Schmoll,66 K. Sedgwick,8 R. Seidl,57,58 A. Sen,21,29,66 R. Seto,8 A. Sexton,43 D. Sharma,64,70 I. Shein,25 T.-A. Shibata,57,67 K. Shigaki,23 M. Shimomura,29,49,68 K. Shoji,35,57 P. Shukla,4 A. Sickles,7,26 C. L. Silva,29,39 D. Silvermyr,41,54 K. S. Sim,33 B. K. Singh,3 C. P. Singh,3 V. Singh,3 M. J. Skoby,45 M. Slunečka,9 R. A. Soltz,38 W. E. Sondheim,39 S. P. Sorensen,66 I. V. Sourikova,7 P. W. Stankus,54 E. Stenlund,41 M. Stepanov,44,* A. Ster,71 S. P. Stoll,7 T. Sugitate,23 A. Sukhanov,7 J. Sun,64 J. Sziklai,71 E. M. Takagui,61 A. Takahara,11 A Takeda,49 A. Taketani,57,58 Y. Tanaka,48 S. Taneja,64 K. Tanida,30,58,62 M. J. Tannenbaum,7 S. Tarafdar,3,69 A. Taranenko,50,63 G. Tarnai,16 E. Tennant,52 H. Themann,64 R. Tieulent,42 A. Timilsina,29 T. Todoroki,57,68 L. Tomášek,28 M. Tomášek,14,28 H. Torii,23 C. L. Towell,1 R. S. Towell,1 I. Tserruya,70 Y. Tsuchimoto,11 T. Tsuji,11 Y. Ueda,23 B. Ujvari,16 C. Vale,7 H. W. van Hecke,39 M. Vargyas,17,71 S. Vazquez-Carson,12 E. Vazquez-Zambrano,13 A. Veicht,13 J. Velkovska,69 R. Vértesi,71 M. Virius,14 A. Vossen,26 V. Vrba,14,28 E. Vznuzdaev,56 X. R. Wang,52,58 Z. Wang,5 D. Watanabe,23 K. Watanabe,68 Y. Watanabe,57,58 Y. S. Watanabe,11 F. Wei,29,52 R. Wei,63 S. N. White,7 D. Winter,13 S. Wolin,26 C. L. Woody,7 M. Wysocki,12,54 B. Xia,53 C. Xu,52 Q. Xu,69

Combinations of immunotherapy with chemotherapy as a first-line treatment for ES-SCLC have generated mixed results. The EXTENTORCH trial assessed toripalimab in combination with chemotherapy as a first-line treatment for patients with ES-SCLC (NCT04012606). Patients with histologically or cytologically confirmed ES-SCLC, stratified by gender and baseline ECOG PS (0 vs. 1) were randomized in a 1:1 ratio to receive 240 mg toripalimab or placebo plus etoposide and cisplatin/carboplatin Q3W for 4-6 cycles, followed by single-agent toripalimab or placebo until progressive disease, intolerable toxicity or up to 2-year treatment. The primary endpoints were PFS as assessed by the investigator per RECIST v1.1 and OS. Tumor mutational burden (TMB) and genomic alterations were assessed by whole-exome sequencing (WES) of tumor tissues. From Sep 2019 to May 2021, 442 patients were enrolled from 48 participating sites in China. 223 and 219 patients were randomized to the toripalimab and the placebo arms, respectively. At data cut off (28 Feb 2022), median follow-up was 11.8 months, a significant improvement in PFS was observed for toripalimab over placebo (5.8 vs. 5.6 months, HR = 0.667 [95% CI: 0.539-0.824], P = 0.0002). Despite 59.4% of patients in the placebo arm received ≥3 additional lines of therapy and 25.6% received a PD-(L)1 inhibitor after the study treatments, OS was significantly improved in the toripalimab arm (14.6 vs. 13.3 months, HR = 0.798 [95% CI: 0.648-0.982], P = 0.0327) at the final OS analysis at data cut off (20 Apr 2023). WES results from 300 patients showed that improvements in PFS and OS were similar irrespective of TMB status. Genomic alterations in integrin-mediated focal adhesion complex were associated with poor prognosis for both PFS and OS in the toripalimab arm. Toripalimab plus chemotherapy had a manageable safety profile, with no new safety signals observed. The addition of toripalimab to chemotherapy provided significant improvements in PFS and OS for patients with ES-SCLC with an acceptable safety profile.

Received 2 October 2023DOI:https://doi.org/10.1103/PhysRevC.108.049905©2023 American Physical SocietyPhysics Subject Headings (PhySH)Research AreasParticle correlations & fluctuationsQuark-gluon plasmaRelativistic heavy-ion collisionsPhysical SystemsBose-Einstein condensatesPionsNuclear Physics

Optimal tumor reduction surgery is crucial for for advanced ovarian cancer (OC) prognosis. Neoadjuvant chemotherapy can increase surgery chances for OC, but the benefit to patients (pts) is limited. PARP inhibitors combined with anti-angiogenic drugs have significant benefits in the first-line maintenance and recurrence treatment of OC. This study aims to evaluate the efficacy and safety of Pamiparib combined with Surufatinib neoadjuvant therapy (NAT) for advanced unresectable OC in the entire population. This is a single-center, single-arm, phase II study following Simon's two-stage design. 20 pts with newly diagnosed unresectable (Fagotti score ≥ 8 or upper abdominal CT score ≥ 3) FIGO III-IV OC were recruited. Enrolled pts will receive NAT with Pamiparib (40 mg bid q3w for 3 cycles) combined with Surufatinib (250mg bid q3w for 2 cycles), followed by interval debulking surgery (IDS) and4 cycles of platinum-containing chemotherapy. The primary endpoint is complete resection rate (R0), and secondary endpoints include objective response rate (ORR), pathologic complete response(pCR) rate, progression-free survival, overall survival, and safety. As of Aug 30, 2023, of the 20 enrolled pts, 16 had completed genetic testing, and 14 were homologous recombination deficiency (HRD) positive, with 9 cases of BRCA1/2 mutations. By Aug 30, 2023, 17 pts completed NAT and IDS with an ORR of 100%. 15 pts achieved R0 surgery (88.24%), and 2 pts achieved R1. All 20 pts were evaluable by GCIG CA125 criteria, and CA125 response was all observed (100%). Grade 3 or 4 treatment-related adverse events that occurred are neutropenia, thrombocytopenia, anemia, and hepatic dysfunction. Pamiparib combined with Surufatinib as a new neoadjuvant "chemotherapy-free" regimen showed extremely high R0 and ORR rates with manageable toxicity profiles. Currently, the experiment is still ongoing and further analysis and reporting of more data will be conducted.

Preclinical research has shown that the combination of radiotherapy and immunotherapy has a synergistic effect, and this has been demonstrated in the survival benefit for patients with locally advanced non-small cell lung cancer. For patients with advanced lung cancer, chemo-immunotherapy has been established as the standard first-line treatment. However, it remains unclear whether the addition of radiotherapy to immunotherapy would result in improved survival outcomes. The purpose of our study was to evaluate the clinical outcomes of advanced lung cancer patients who received immunotherapy-containing treatment with or without radiotherapy.